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norepinephrine analog radiotracer [4].
Patients admitted to the HF outpatient at the Pró-Cardíaco Hospital
were recruited through a clinical screening. Eligibility criteria involved
(1) age ≥ 18 years, (2) New York Heart Association (NYHA) Classes I–
III, (3) left ventricular ejection fraction ≤ 50% (echocardiography) and
(4) no alternative cause for the symptoms. Enrollment was stratiﬁed
into two groups on the basis of the current adherence of patients to con-
ventional therapy alone (Control–Statin naive) or in combination with
daily statin administration (Statin). Drug prescription did not changeCardiac sympathetic drive provides inotropic support to the failing
heart and preserves cardiovascular homeostasis. As myocardial insult
evolves, the sympathetic compensatory response contributes to a
progressive decline in the cardiac contractile function, increases the
vulnerability to arrhythmias and constitutes an independent mortality
predictor [1]. Despite optimal treatment with standard drugs, the re-
maining cardiac sympathetic overactivity in patients with heart failure
(HF) highlights themodulation of adrenergic system as a primary target
in the disease treatment.
An attenuation of the cardiac sympathetic overactivity in animals
with pacing-induced HF has been suggested as a pleiotropic effect of
the HMG-CoA reductase inhibitor – statin – administration [2]. Never-
theless, the translation of these ﬁndings into human failing heart
remains unknown since there has been inconclusive evidence [3] of statin
inﬂuence on cardiac sympathetic overactivity. Therefore, the purpose of
this cross-sectional study was to determine whether statin therapy is as-
sociated with a reduced cardiac sympathetic drive in patients with HF.
The indicator of sympathetic drive to the heart was obtained via myocar-ces, Department of Physiology
rofessor Hernani Pires de Melo,
razil. Tel.: +55 21 26292403.
).
.dial imaging with 123Iodine-metaiodobenzylguanidine (123I-MIBG), a
for at least 4 weeks before the study. Eligible patients provided a
consent form after receiving verbal and written details regarding the
procedures adopted in the study, which was approved by the Ethics
Committee of the Antonio Pedro University Hospital.
Cardiac sympathetic activity was assessed via 123I-MIBG myocardial
scintigraphy. Patients continued on medication since drug prescription
did not involve agents that interact with MIBG uptake. Early and late
myocardial anterior planar images were, respectively, acquired 30 min
and 4 h after the radiotracer infusion. Derived from the scintigraphic
planar images, semi-quantitative myocardial 123I-MIBG uptake and
washout reﬂected functional/structural cardiac innervation and sympa-
thetic tone, respectively [4]. Data are presented as mean ± SEM. Cate-
gorical variables were analyzed through a chi-square test. A two-tailed
unpaired Student's t-test was performed to identify signiﬁcant
between-group differences in normally distributed variables. Statistical
signiﬁcance was accepted at the 0.05 level. Groups presented compara-
ble clinical characteristics. However, a higher frequency of NYHA func-
tional classiﬁcation II patients was observed in the statin users. The
control group was composed by a higher number of NYHA functional
classiﬁcation III patients (Table 1). Patients under statin administration
presented lower WR whereas early and late H/M were equivalent for
both groups (Fig. 1).
This study was designed to determine whether statin treatment is
associated with attenuation of the cardiac sympathetic activity in
humans with HF, an effect observed in an experimental model [2]. Our
ﬁndings suggest that statin therapy reduces cardiac sympathetic activi-
ty in patients with HF without changing its functional/structural inner-
vation. Compelling evidence indicates survival improvement as a
Table 1
Demographic and clinical characteristics of the heart failure patients under conventional
pharmacological therapy alone (Control) or in combination with daily statin administra-
tion (Statin).
Variables Control (n = 9) Statin (n = 8)
Gender (female/male) 5/4 3/5
Age (years) 53 ± 4 58 ± 2
BMI (kg/m2) 29.1 ± 2.5 26.5 ± 1.3
NYHA (I/II/III) 1/1/7 0/6⁎/2⁎
LVEF (%) 30.6 ± 0.6 33.7 ± 0.5
SBP (mm Hg) 131.3 ± 5.4 139.1 ± 5.2
DBP (mm Hg) 86.3 ± 4.2 89.6 ± 4.9
Total cholesterol (mg · dL1) 170.7 ± 13.5 179.8 ± 13.2
Medications
Aspirins 2 5
ACE Inhibitors 3 4
Calcium channel blocker 2 2
Nitrates 2 3
β-blockers 1 I
ACE — Angiotensin-converter enzyme; BMI — Body mass index, DBP — Diastolic blood
pressure, HDL — High-density lipoprotein, LDL — Low-density lipoprotein, LVEF — Left
ventricular ejection fraction, SBP — Systolic blood pressure.
⁎ P b 0.05 — Statin vs. Control
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malization of afferent input and central integration of autonomic bal-
ance [6]. Besides the normalization of renal [7] and muscle
sympathetic [8] outﬂow, oral statin treatment also increases heart rate
variability in patients with HF [9]. In addition, our ﬁndings strengthen
the concept that statin therapy also has an impact on the autonomic
control of the failing heart and conﬁrm the long-term treatment in-
duced decrease in the cardiac sympathetic activity [3].
Accelerated myocardial 123I-MIBG washout rate has been reported
as a representative marker of the failing heart [10] and its predictive
power for cardiac death [1] adds potential clinical perspective to the
ﬁndings of the present study. The lipid proﬁle homogeneity of the sam-
plemay indicate that statin pleiotropic propertiesmay have contributed
to the reduced cardiac sympathetic activity. NYHA functional classes
were not equally distributed in the groups of the study and their inﬂu-
ence on washout rate may not be discarded. Similarity in the remaining
clinical characteristics of the sample and commonly prescribedmedica-
tions also corroborate the belief that HMG-CoA reductase inhibitors
may contribute to the washout behavior in the group under daily statin
administration.
Myocardial 123I-MIBG imaging consistently tracks favorable clinical
consequences of pharmacological interventions [3]. Nonetheless, no
functional/structural innervation changes were evidenced as a result
of the statin therapy. Potential reasons for this unexpected ﬁnding
might be related with the duration of pharmacological therapy and
the lipophilicity properties of the statins. Whereas functional/structural
innervation adaptations have been related to long-term therapy
(6 months) [3], our study only included patients that were underFig. 1. Early and late H/M ratio and washout rashorter duration range of statin administration (1–2 months). In addi-
tion, increases in the H/M ratio were only observed when lipophilic
statins were administered [3], which was not always the case in this
present study.
Potential methodological limitations of the present study involve
those related to cross-sectional designs for inferring causality, sample
characteristics and statin therapy protocol. The cross-sectional design
was preferred to avoid needless thyroidal uptake and radioactivity ex-
posure, whereas the small sample size resulted from the difﬁculty to re-
cruit matched patients with HF under conventional and statin therapy.
Despite a potential low statistical power, the analysis was able to dis-
close the difference between the groups. In addition, medication dose
was not strictly controlled, since it was exclusively determined with
basis on clinical needs. While this limitation does not allow inferences
on the precise dose related to the statin-induced decrease in the cardiac
sympathetic drive, drug prescription and its amount presented low
inter-subject variability.
In summary, statin therapy is associated with reduced cardiac sym-
pathetic activity in patients with HF without changes in functional/
structural innervation. The potential relevant clinical perspective raised
through these ﬁndings deserves additional prospective data to conﬁrm
the impact of statin therapy on the cardiac sympathetic hyperactivity in
patients with HF.
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